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A B S T R A C T
Oncofetal fibronectin (FN-EDB) and tenascin-C C domain (TNC-C) are nearly absent in extracellular matrix of
normal adult tissues but upregulated in malignant tissues. Both FN-EDB and TNC-C are developed as targets of
antibody-based therapies. Here we used peptide phage biopanning to identify a novel targeting peptide (PL1,
sequence: PPRRGLIKLKTS) that interacts with both FN-EDB and TNC-C. Systemic PL1-functionalized model
nanoscale payloads [iron oxide nanoworms (NWs) and metallic silver nanoparticles] homed to glioblastoma
(GBM) and prostate carcinoma xenografts, and to non-malignant angiogenic neovessels induced by VEGF-
overexpression. Antibody blockage experiments demonstrated that PL1 tumor homing involved interactions with
both receptor proteins. Treatment of GBM mice with PL1-targeted model therapeutic nanocarrier (NWs loaded
with a proapoptotic peptide) resulted in reduced tumor growth and increased survival, whereas treatment with
untargeted particles had no effect. PL1 peptide may have applications as an affinity ligand for delivery of di-
agnostic and therapeutic compounds to microenvironment of solid tumors.
1. Introduction
Targeting of anticancer drugs with affinity ligands, such as anti-
bodies and homing peptides, is widely used to achieve a balance be-
tween increased drug concentration at the tumor site and reduced
systemic exposure [1,2]. In particular, antibody drug conjugates (ADCs)
have seen clinical successes with 4 ADCs clinically approved and>100
in different stages of clinical testing [3]. However, antibodies are ex-
pensive to manufacture and show poor tissue penetration due to a
combination of large size and high affinity [4]. In vivo peptide phage
display, an agnostic explorative technique, has been used to probe
vascular heterogeneity of live animals and to identify tumor homing
peptides [5]. As phage used for in vivo display is a nanoparticle itself,
the peptides are particularly well-suited for delivery of nanoparticle
payloads [2]. Homing peptide target molecules (receptors) include
different cell surface molecules: e.g., αv-integrins, NRP-1, folate re-
ceptor alpha, Ephrin receptor A2 (EphA2), molecules aberrantly ex-
pressed on the surface of tumor and stromal cells (e.g. p32, nucleolin,
and calreticulin), components of blood clots, and the tumor extra-
cellular matrix (ECM) [6–12].
Certain ECM proteins (e.g., periostin, hyaluronan, certain collagens,
laminins, perlecan, fibronectin, and tenascins) are over-represented in
the tumor microenvironment and may provide a more stable and high
capacity target for affinity delivery than antigens expressed on the cell
surface [13]. Alternatively spliced fibronectin Extra Domain-B (FN-
EDB) and Tenascin-C (TNC) are overexpressed in many solid tumors
[14–16]. TNC isoform C (TNC-C) shows particularly low baseline ex-
pression in non-malignant tissues and a robust upregulation in solid
tumors such as malignant brain tumors and lung carcinoma [14,15].
The FN-EDB and TNC antibodies (FN-EDB ScFV L19, TNC-C ScFV G11,
F16, and 81C6) are used for precision delivery of cytokines (e.g., IL2,
TNF) and radionuclides [17,18]. In addition, these antibodies are
evaluated as diagnostic imaging agents for immuno-PET, SPECT/CT
and radioimmunotherapy in malignant primary and metastatic brain
tumors, and in head- and neck squamous cell carcinomas [17–19].
Importantly, recent studies demonstrate that ECM-directed non-
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internalizing antibodies can be used to potentiate the cytotoxic activity
of intracellularly acting cytotoxic drugs [20].
Simultaneous affinity targeting of multiple molecules in the tumor-
associated ECM is advantageous over targeting one receptor at the time.
First, expression of the tumor ECM is heterogeneous and multitargeting
may result in a more uniform biodistribution of payloads. Secondly,
dual targeting may alleviate issues related to limited number of avail-
able receptors for affinity ligands - a major bottleneck in affinity tar-
geting [21].
Here we identified a novel bispecific peptide (PL1; amino acid se-
quence: PPRRGLIKLKTS) that recognizes both FN-EDB and TNC-C and
show that this dual-targeted peptide can be used for robust and specific
delivery of imaging agents and therapeutic payloads to solid tumors.
2. Materials and Methods
2.1. Materials
Phosphate-buffered saline (PBS) was purchased from Lonza
(Verviers, Belgium), K3[Fe (CN)6], HCl, Nuclear Fast Red, Xylene sub-
stitute, isopropanol, Triton-X, Tween-20, CHCl3, MeOH, and di-
methylformamide (DMF) were purchased from Sigma-Aldrich (Munich,
Germany). Cloning, expression, purification of proteins (FN-EDB, TNC-
C, NRP1, NCL and single chain antibodies FN-EDB-L19 and TNC-C-
G11), and generation of polyclonal rabbit antibodies are described in
Supplementary Information, Materials and Methods section.
2.2. Cell lines
U87MG and PC3 prostate carcinoma cells were obtained from
ATCC, and NCH421K cells from CLS Cell Lines Service GmbH
(Eppelheim, Germany). WT-GBM and VEGF-KO GBM cells were a kind
gift from Gabriele Bergers (Leuven, Belgium).
2.3. Clinical samples
Fresh surgical samples of GBMs were obtained from Tartu
University Clinics, Tartu, Estonia under protocols approved by the
Ethics Committee of the University of Tartu, Estonia (permit #243/
T27).
2.4. Animal experiments
Animal experimentation procedures were approved by the Estonian
Ministry of Agriculture, Committee of Animal Experimentation, project
#42 and #48. Athymic nude mice (HD) were housed in a pathogen-free
environment at the Animal Facility of the Institute of Biomedicine and
Translational Medicine, University of Tartu (Tartu, Estonia). For tumor
modeling, we used nude mice bearing orthotopic GBM (NCH421K,
U87MG and, WT-GBM) and s.c. prostate carcinoma (PC3). For ortho-
topic GBM induction, the mice were placed into the ear bars of a ste-
reotactic frame, a midline incision was made using a scalpel exposing
the sagittal and coronal sutures, and a burr hole was scraped through
the skull 0.5 mm anterior to the bregma and 2.5mm lateral to the
midline using a syringe. GBM 300,000 cells in 3 μL PBS were injected at
a depth of 3mm with a Hamilton syringe over 4min, and the needle
was removed 5min after the injection. Bone wax was used to close the
burr hole, the surface was cleaned with a sterile cotton swab, and the
skin was closed by sutures.
2.5. Phage biopanning
We used for biopanning the NNK-encoded cyclic CX7C, and linear
X7 peptide libraries (diversity ~ 5×108) displayed on T7 415-1b
phage scaffold (Novagen, EMD Biosciences, MA, USA). To identify
bispecific peptides that interact with both TNC-C and FN-EDB, we
performed cross screens on both targets. During the first round of se-
lection, microtiter plates coated with 20 μg/ml recombinant purified
TNC-C were blocked with PBS containing 1% bovine serum albumin
(BSA), followed by incubation with 5× 108 pfu of phages in PBS at 4 °C
overnight, by washes to remove background, and by phage rescue and
amplification in BLT5403 strain of E. coli (Novagen, EMD Biosciences,
MA, USA) [5]. The following rounds of biopanning were carried on Ni-
NTA Magnetic Agarose Beads (QIAGEN, Hilden, Germany) coated with
hexahistidine-tagged FN-EDB (3 μg/μl beads) at room temperature.
After 5 rounds of selection, a set of random clones was sequenced, and
individual peptide-phage clones and control (G7 peptide-displaying or
insertless) phages were incubated with FN-EDB and TNC-C-coated
magnetic beads. RPARPAR phage and His-tagged NRP-1 b1b2 domain
were used as positive control [22]. To address the specificity of the
peptide phage binding to the FN-EDB and TNC-C, the protein-coated
beads were pre-incubated with 20 μg/ml blocking rabbit polyclonal
antibodies.
2.6. Synthesis of peptides and nanoparticles
The peptides were synthesized in-house or ordered from TAG
Copenhagen (Frederiksberg, Denmark). Peptides were synthesized
using Fmoc/t-Bu chemistry on the microwave-assisted automated pep-
tide synthesizer (Liberty, CEM Corporation, NC, USA), purified by HPLC
using 0.1% TFA in acetonitrile-water to 90%–95% purity, and validated
by Q-TOF mass spectral analysis. All peptides were synthesized with
free carboxyl termini; 5(6)-carboxyfluorescein (FAM) or biotin was at-
tached via the 6-aminohexanoic acid spacer to the N-terminus of the
peptide. The iron oxide nanoworms (NWs) were prepared according to
a published protocol by Ref. [23] with minor modifications. The ami-
nated NWs were PEGylated using maleimide-5K-PEG-NHS. Peptides
were coupled to NWs through a thioether bond between the thiol group
of a cysteine residue added to the N-terminus of the peptide and the
maleimide on the functionalized particles. Isotopically pure silver na-
noparticles (AgNPs) were synthesized and functionalized as previously
described [6]. For more details on nanoparticle preparation and char-
acterization, see Supplementary Information, Materials and Methods
section.
2.7. Cell-free peptide-binding assay
The FAM-labeled peptides were coated on ELISA plates (Nunc
Maxisorp, Thermo Fisher Scientific Inc., MA, USA), blocked with PBS
containing 1% BSA, and incubated with recombinant proteins at 2μg/
well in PBS for 6 h. The protein was detected using an anti-His-tag
antibody, followed by horseradish peroxidase-conjugated secondary
antibody, chromogenic reaction, and measurement of absorbance at
450 nm with a microplate reader (Tecan Austria GmbH, Grödig,
Austria).
2.8. Laser ablation ICP-MS-based AgNP biodistribution studies
Isotopically pure Ag107NPs and Ag109NPs were prepared as de-
scribed [6] and functionalized with biotinylated PL1 peptide (PL1-
Ag109NPs) or biotin (biotin-Ag107NPs) particles. PL1-functionalized and
control AgNPs were mixed at 1:1 ratio and injected i.v. in nude mice
bearing U87MG orthotropic GBM. 5 h later, the mice were perfused via
the left ventricle of the heart with 20mL PBS. Organs were snap-frozen
for cryosectioning and ICP-MS analysis. Snap-frozen organs were
cryosectioned (30 μm) and stored at −20 °C. Before the LA-ICP-MS
analysis, the samples were thawed and dried in a desiccator.
Mapping of 109Ag and 107Ag isotopes on tissue sections (2-D map-
ping and line scans) was performed using a Cetac LSX-213 G2+ laser
ablation (LA) system using a HelEx 2-volume ablation cell, coupled to
Agilent 8800 QQQ ICP-MS. The LA-ICP-MS setup was optimized using
NIST 612 glass. Main parameters for LA–ICP–MS are shown in Table S1.
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13C, 107Ag, and 109Ag isotopes were detected with dwell times of 9.5
and 14ms respectively, corresponding to a duty cycle of 0.05 s 13C was
used as an internal standard to account for differences in the volume of
ablated tissue. Data reduction and elemental and isotope ratio maps
were constructed using Chromium 2.2 and Iolite v3.62 software.
Multiple parallel line raster scans were performed to generate dis-
tribution maps. The raster lines were directly adjacent to each other
(with 65 μm offset) and the whole mapping area was ablated. A typical
sample area was ~14×8mm, and run time for a single sample was
~4 h.
2.9. In vivo NW biodistribution studies
NWs (7.5mg/kg) in PBS were injected into the tail vein of the
tumor-bearing mice, followed by cardiac perfusion with 20ml PBS/
DMEM before collection tumor and control organs for imaging. In
control experiments, NW injection was preceded by systemic pre-in-
jection of blocking FN-EDB and/or TNC-C antibodies (30 μg/mouse)
15min prior to injection of the NWs.
2.10. Confocal microscopy
Snap-frozen 10 μm tumor cryosections were mounted on
Superfrost™+ slides. The sections were equilibrated at RT and fixed
with 4% paraformaldehyde or methanol and permeabilized with PBST
(PBS+ 0.05% Tween 20), blocked with PBST, 5% BSA, 5% goat serum
(GE Healthcare, Little Chalfont, UK) at RT for 30 min, followed by
primary antibody incubation at RT for 1 h. The primary antibodies were
rabbit anti-fluorescein IgG (cat. no. A889, Thermo Fisher Scientific,
MA, USA), rat anti-mouse CD31 (BD Biosciences, CA, USA), mouse anti-
human nestin (#MA1-110, Thermo Fisher Scientific Inc.), rat anti-
mouse CD31, rat anti-mouse CD11b (cat. no. 553370; 557395, BD
Biosciences, CA, USA), rat anti-mouse LYVE-1 (cat. no. 14044382,
eBioscience, CA, USA), rat anti-mouse CD68 (#MCA1957A488, Bio-
Rad, CA, USA), rabbit polyclonal anti-Ki67 (cat. no. NB500-170,
Novusbio, UK), and rabbit anti-cleaved caspase-3 (cat. no. 966, Cell
Signaling Technology, MA, USA), and in-house prepared CF647 (or
CF546)-labeled single chain antibodies ScFV L19 (against FN-EDB) and
ScFV G11 (against TNC-C). The secondary antibodies, Alexa 488 goat
anti-rabbit IgG, Alexa 647 goat anti-rat IgG, and Alexa 546 goat anti-
mouse IgG, were from Invitrogen (USA). Nuclei were counterstained
with DAPI (Molecular Probes) at 1 μg/ml. The coverslips were mounted
on glass slides with Fluoromount-G (Electron Microscopy Sciences, PA,
USA), imaged using confocal microscopy (Olympus FV1200MPE,
Tokyo, Japan) and analyzed using the FV10-ASW4.2 viewer, Imaris
software and ImageJ freeware.
2.11. NW overlay assay
Fresh surgical GBMs (obtained during autopsy) were snap-frozen in
liquid nitrogen, cryosectioned at 8 μm, fixed with methanol, and per-
meabilized with TBS followed by blocking buffer containing 5% BSA,
Fig. 1. Identification of bispecific peptide targeting FN-EDB and TNC-C. (A) Biopanning using T7 phage-displayed X7 peptide library on immobilized TNC-C and FN-
EDB resulted in ~3000-fold enrichment in binding to FN-EDB in round 5 of selection. (B) Genomic DNA and amino acid sequence of the C-terminal portion of the T7
major coat protein 10 and the adjacent exogenous PL5 peptide (underlined); single nucleotide deletion in the peptide-encoding DNA is indicated by an arrow. PL5
and its shorter derivative PL1 peptide retain the ability to bind both target proteins. (C) PL1 phage binds to immobilized FN-EDB and TNC-C. The specificity of PL1-
phage binding to EDB and TNC-C was evaluated by preincubation of protein-beads with 50 μg/ml of anti-FN-EDB or anti-TNC-C blocking antibody. PL1 phage
binding is expressed as fold over control phage displaying heptaglycine. (D) Synthetic PL1 peptide interacts with FN-EDB and TNC-C proteins. Immobilized FAM-PL1
was probed with recombinant His-tagged EDB and TNC-C (or control BSA), followed by sequential incubation with rabbit anti–His-tag primary antibody, secondary
goat anti-rabbit HRP antibody and a chromogenic peroxidase reaction. Values represent mean ± standard deviation from 3 independent experiments; P-values were
determined by Student unpaired t-test; all statistical tests were two-sided; *P < 0.05; **p ˂ 0.01; ****p < 0.0001.
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5% goat serum and 5% FBS in TBS. For overlay, the sections were in-
cubated with 20 μg/slide of PL1-NW or NW at 4 °C overnight. The
sections were washed and blocked with blocking buffer, followed by
immunostaining using rabbit anti-fluorescein primary antibodies and
detection with the Alexa-488 anti-rabbit secondary antibody. FN-EDB
and TNC-C were detected by fluorescently labeled single-chain anti-
bodies ScFV L19 FN-EDB-CF647 and ScFV G11 TNC-C-CF555.
2.12. In vivo angiogenesis model and multiphoton intravital imaging
Angiogenesis was induced by injecting 2.5× 108 PFU of an adeno-
viral vector driving expression of mouse VEGF164 (Ad-VEGF164) in-
tradermally into the left ear of 7–8 week-old female nude mice [24].
The right ear served as a control. PL1-NW or NW (at 7.5 mg/kg) were
i.v. injected 4 days after induction of angiogenesis and 24 h before in-
travital imaging. Texas Red/Evans Blue was i.v. injected at 30mg/kg to
allow visualization of blood vessels. The ear was fixed on the coverslip
for imaging using a veterinary-grade glue tape, and a mold was pre-
pared around the ear from agarose for imaging. The body temperature
was maintained throughout the experiment with a heat mat. Images
and videos were acquired at an excitation wavelength of 920 nm, op-
tical sections were taken under identical conditions, and experiments
were repeated in triplicates. Intravital imaging was performed with
multi-photon laser scanning fluorescence microscope (Olympus
FV1200MPE-BX61WI) equipped with MaiTai DeepSee IR laser (Spectra-
Physics) and with XLPLN25x/1.05 NA water-immersion objective
(Olympus).
2.13. Magnetic resonance imaging
For MRI, nude mice bearing orthotopic NCH421k GBM were i.v.
injected with iron oxide nanoworms at 5 mg/kg. Five hours after NW
injection, the mice were anesthetized with isoflurane and subjected to
MRI using a 9.4 T BioSpec 94/21 (Bruker BioSpin MRI GmbH,
Ettlingen, Germany) equipped with ParaVision Acquisition 6.0.1 soft-
ware (Bruker, Ettlingen, Germany). Following intravital MRI, the ani-
mals were perfused with PBS to remove blood and background circu-
lating NWs and subjected to postmortem MRI. After imaging, tumors
and control tissues were harvested and sectioned for immuno-
fluorescence staining. Mice received isoflurane in oxygen mix (1.5%,
flow rate of 200 ml/min) for anesthesia; the body temperature and
breathing rate were monitored throughout the experiments. T2* map
MGE (Multiple Gradient Echo) sequences were acquired in sagittal and
coronal orientations. The following parameters used during the data
acquisition were the following: slice thickness, 0.375 mm (3 slices
averaged offline for improved signal/noise ratio); inter-slice gap:
0.375 mm; repetition time: 800; Echo time: 3.5–38.5 ms; flip angle: 50°;
number of axial slices: 128; pixel bandwidth: 292.9; imaging frequency:
400.3; matrix: 256 × 256; magnetic field strength: 9.4. To calculate T2
relaxation times, regions of interest (ROIs) were drawn manually on the
images by using image sequence analysis (ISA) tool package (Paravision
5, Bruker) using T2vtr fit function y = A + C*exp (-t/T2) (A: absolute
Fig. 2. Systemic PL1-NWs home to glioblastoma lesions. (A, B, C) NWs coated with FAM-labeled PL1 peptide or control FAM-NWs were i.v. injected at 7.5 mg/kg into
mice bearing s.c. U87MG (A), orthotopic NCH421K (B), and orthotopic WT GBM (C) glioblastoma xenografts. After 5 h circulation, the mice were perfused through
the heart with PBS/DMEM and organs were collected. Cryosections were immunostained with antibodies against fluorescein to visualize NWs (green), endothelial
cells (CD31, red), and stem cell-like cells (nestin in NCH421K, magenta) and examined using confocal microscopy. Images acquired under same conditions from
tumor sections from mice injected with control non-targeted FAM-NWs are shown in the boxes). The arrows point to PL1-NWs (green) along the tumor blood vessels
and the arrowheads point to extravasated PL1-NWs. FAM signal was quantitated by Fiji ImageJ (A-C, bar charts on the right). (D) Specificity of in vivo homing of PL1
nanoparticles probed with antibody blockade. PL1-NWs (7.5 mg iron/kg body weight) alone, or in combination with individual anti-EDB, or anti-TNC-C antibodies,
or a cocktail of both antibodies, were i.v. injected into mice bearing U87 xenograft tumors. Five hours after the injection, the mice were perfused through the heart
with PBS/DMEM and organs were collected for cryosectioning and examination by confocal microscopy. Arrows point to PL1-NWs (green) in tumor tissue. Nuclei
were stained with DAPI (blue). The FAM signal was quantified from representative images using Fiji ImageJ. Error bars, mean ± SEM (N=3–6 mice per group);
scale bars: 100 μm; p-value was determined using Student unpaired t-test, two-tailed; ns P > 0.05; *P < 0.05; **p ˂ 0.01; ****p < 0.0001.
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bias; C: signal intensity; T2: spin-spin relaxation time) for T2 evalua-
tion. To calculate mean signal intensity in the tumor to a reference
region, ROIs were drawn manually on the images at given echo time
(TE). Experiments were repeated in triplicate.
2.14. Experimental tumor therapy
U87MG cells (4× 106 cells) in 100 μl PBS were implanted sub-
cutaneously into the right flank of 11–15 week old male nude mice. The
weight of animals and tumor volume [length× (width x width)/2] was
recorded on every other day until tumor volume reached ~100mm3.
Animals were randomized into 4 groups (PBS, FAM-D[KLAKLAK]2-NWs,
FAM-PL1-NWs, and FAM-PL1-D[KLAKLAK]2-NWs; 8 mice/group).
100 μl of NWs (at 5mg/kg body weight of iron) or PBS was in-
travenously injected into the tail vein every other day for ten injections.
Tumor size, body weight, survival, and behavior were recorded during
treatment and post-therapy. When the tumor volume reached
2000mm3 (or> 10% body weight), the mice were sacrificed, and or-
gans and tumors were excised, macroscopically observed and snap
frozen. Tumor volume, Kaplan–Meier survival and body weight curves
were calculated using the GraphPad Prism 6 software with p-va-
lues< 0.05 considered significant. For experimental therapy on in-
tracranially-implanted NCH421k GBM, 32 tumor mice were
randomized into 4 groups 3 days after the tumor implantation. 100 μl of
the PBS or PBS containing FAM-D[KLAKLAK]2-NWs, FAM-PL1-NWs and
FAM-PL1-D[KLAKLAK]2-NWs (5mg/kg body weight of iron) were in-
jected i.v. every other day for 10 total injections. Tumor size, body
weight, survival, and behavior were recorded during and post-treat-
ment. Kaplan–Meier survival and body weight curves were calculated
using GraphPad Prism 6 and P values < 0.05 were considered sig-
nificant.
2.15. Statistical analysis
Prism 6 software was used to perform statistical analyses. The re-
sults are presented as mean with error bars indicating± SEM. For
comparison of 2 groups, we used unpaired t-test or ANOVA test
(p < 0.05 was considered significant). P-values were considered as
follows: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and p****≤0.0001.
Details of analysis are shown in Table S3.
For animal study, the sample size was estimated on the basis of
previous experiments yielding effect size 1,2 and 2.3 respectively [7]
and unpublished data. Therefore, we conservatively assume effect size
of 1.5 for sample calculation. To have at least> 80% probability of
detecting a difference in means between the control and peptide-con-
jugated nanoparticle group of 2.2 standard deviations, we assigned a
Fig. 3. T2-weighted and T2* MRI of orthotopic NCH421K glioma mice. NCH421K glioblastoma mice were i.v. injected with PL1-NWs or control NWs (5 mg/kg iron).
(A) Axial slice views of T2-weighted images prior to NW injection (pre-scan), at 5 h after NW circulation (post-scan), and terminal images after perfusion with PBS to
remove blood and circulating NWs (perfused; T, tumor). Note increased dark signal in a tumor of a mouse injected with PL1-NWs (arrows), but not with control NWs.
Insets: coronal T2-weighted views of same tumor. Representative images from 3 independent experiments are shown. (B) T2 parametric image (T2* map) used for T2-
relaxation time plot, showing targeted and non-targeted NW relaxation time in ms. P-value was determined by one-way ANOVA with Dunnett's multiple comparisons
test in comparison with pre-scan; *P < 0.05; ***P < 0.001; ****p < 0.0001, error bars: mean ± SEM, (3 mice per group, for each time point 10–11 data points/
mouse). (C) Confocal imaging of cryosections from mice used for MRI studies. Green: NWs, magenta: anti-human nestin; blue: nuclei stained with DAPI; White arrows
point to localization of PL1-NWs in the tumor (T) defined by the presence of high nuclear density; BP - normal brain parenchyma. The dotted line shows the tumor
margin. Scale bars, 100 μm.
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sample size of 8 mice in each treatment group. Sample size calculations
were performed in PASS (NCSS 2008) or G Power [25] power analysis
software using the Inequality Tests for Two Means procedure. NCH421k
animals were blindly assigned to experimental or control groups. U87
animals were randomly assigned to experimental or control groups
once tumor reached 100mm3. None of the animals were excluded from
the analysis. No blinding was used during the experiment. Our ex-
perimental design ensures that minimal bias (or noise) is introduced,
that could be mistaken as being treatment effects (by ensuring same
sex, similar animal weight at start of experiment, same animal age,
same type of stabling, several animals caged together).
3. Results
3.1. Identification of a bispecific TNC-C and FN-EDB binding peptide
For selection of bispecific peptides for FN-EDB and TNC-C, we em-
ployed cross-screening of X7 peptide libraries displayed on T7 phage on
recombinant human FN-EDB and TNC-C fragments (Figs. S1 and S2).
The first round of biopanning was performed on TNC-C immobilized on
polystyrene multiwall plates, followed by several rounds of selection on
hexahistidine-tagged FN-EDB coated onto magnetic Ni-NTA beads. By
round 5,> 1000 fold enrichment in phage binding was seen (Fig. 1A).
Whereas most of the 48 peptide phages individually tested from round
5 pool conferred phage binding to either target alone, a 27-amino acid
(aa) peptide PPRRGLIKLKTSSNTKENSVVASLRP (PL5) possessed the
desired dual binding ability (Fig. S3). The genome of the PL5 phage
harbored a single nucleotide deletion in the peptide-encoding segment
resulting in frameshift and conversion of 7-aa peptide displayed at the
C-terminus of the phage major capsid protein to a 27-aa peptide
(Fig. 1B). We created a panel of shorter derivatives of the PL5 peptide
and found that 12-aa peptide, which we designated PL1 (PPRRGLIKL-
KTS), retained the ability to bind to both FN-EDB and TNC-C when
displayed on phage particles (Fig. 1C) and as a synthetic FAM-labeled
peptide (Fig. 1D). The binding was specific: PL1 phage did not interact
with a recombinant control protein NRP-1, and the phage binding was
inhibited by function-blocking polyclonal antibodies against FN-EDB
and TNC-C (Fig. 1C). Alanine scanning mutagenesis showed that the
PL1 peptide interacts with FN-EDB and TNC-C using an overlapping
binding site, with L6 and T11 playing a critical role in both interactions
(Fig. S4).
3.2. PL1-functionalized iron oxide nanoparticles home to tumor lesions
To explore the utility of PL1 peptide as a systemic tumor-targeting
probe, we first studied the effect of PL1 coating on biodistribution of
dextran-coated PEGylated paramagnetic iron oxide nanoworms (NW) –
a model nanoscale agent used for systemic affinity targeting as a drug
carrier and an MRI contrast agent [23]. PL1-NWs (Fig. S5) were audited
for homing upon systemic administration in mice bearing orthotopic
GBM (NCH421K, WT-GBM), s.c. GBM (U87MG), and prostate carci-
noma (PC3) xenografts. Compared to non-targeted control NWs, PL1
functionalization increased accumulation of the NWs in the tumor
perivascular matrix in all models tested (Fig. 2, Fig. S6). Compared to
non-targeted NWs, the increase in PL1-NW accumulation after 5 h cir-
culation was 8.8-fold in NCH421K, 5-fold in U87MG, 3.3-fold in WT,
and 4.7-fold in PC3 tumors, whereas in the control organs (the liver,
kidney, spleen, and lung) the signal for PL1-functionalized and non-
targeted NWs was similar (Figs. S5 and S6). The fluorescence micro-
scopy data were confirmed by Prussian blue histochemical staining for
iron and light microscopy (Fig. S8). Preferential accumulation of PL1-
NWs in NCH421k tumor tissue was also seen at 24 h time point (Fig.
Fig. 4. PL1 NWs home to nonmalignant angiogenic vessels. (A) Left ear of nude athymic mice was intradermally injected with Ad-VEGF-A164; 4 days later, the
angiogenic response was apparent, and the animal was injected with PL1-NWs for homing studies and multiphoton imaging after 24 h. (B) PL1-NWs accumulate in
the angiogenic blood vessels. (C) Non-targeted NWs show no homing to the Ad-VEGF-A164 induced angiogenic site. (D, E) PL1-NWs and nontargeted NWs show no
signal in the normal ear vessels. Green: PL1-NWs or NWs; red: blood vessels stained by Texas Red/Evans Blue, the dashed white lines delineate the vascular tree,
arrows point to PL1-NWs in the angiogenic vessels. Scale bars: 20 μm. (F) Quantification of FAM signals in representative images (mean pixel intensity). Error bars:
mean ± SEM (N=3 mice per group), statistical analysis: p-value determined using two-tailed unpaired t-test; ***P < 0.001.
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S6).
We next studied the relationship between the tumor homing pattern
of the PL1-IONWs and the distribution of the FN-EDB and TNC-C im-
munoreactivities. Cryosections of U87MG and NCH421K tumors from
PL1-NW-injected mice were stained with FN-EDB-specific (ScFV L19)
and TNC-C-specific (ScFV G11) single-chain antibodies. Compared to
normal organs, FN-EDB and TNC-C were upregulated in tumors (Fig.
S9) and PL1-NW signal in tumor tissue showed extensive overlap with
FN-EDB and TNC-C immunoreactivities (Fig. S10). Coadministration of
PL1-NWs with blocking rabbit polyclonal antibodies against either FN-
EDB or TNC-C resulted in a significant decrease in tumor homing and a
cocktail of both FN-EDB and TNC-C antibodies almost completely in-
hibited the tumor accumulation of PL1-NWs (Fig. 2D). These results
show that PL1-NWs home to tumor tissue in FN-EDB and TNC-C-de-
pendent manner.
The elongated shape of NWs not only contributes to their ability to
attach to target cells but also enhances magnetic relaxivity in MRI [23].
MRI was performed on NCH421K GBM mice pre-injection, 5 h after
administration of systemic NWs and after terminal imaging. As shown
in Fig. 3, T2-weighted and T2* images of tumors from mice injected
with PL1-NWs tumors displayed a hypointense signal (Fig. 3). In con-
trast, in animals injected with nontargeted NWs, no changes in signal
intensity within the tumors were observed under the same imaging
conditions. In PL1-NW-injected mice, T2* relaxation time within the
tumor decreased by 27–36% (from about 23 ± 2 ms to 17 ± 1 ms and
14 ± 4 ms). In mice injected with nontargeted NWs, relaxation time
remained the same (21 ± 5 ms vs 22 ± 3 and 20 ± 6). Post-MRI
confocal fluorescent imaging confirmed selective accumulation of PL1-
NW in the GBMs (Fig. 3C). NCH421k is a clinically relevant stem cell-
like GBM of intermediate phenotype and staining of tumor sections
with anti-human stem and progenitor cell marker nestin antibodies was
used to highlight the cancer stem cell-like cells (Fig. 3C). PL1-NWs were
detected throughout the GBM lesions, including in the areas rich in
nestin-positive cells. These results suggest potential applications for
PL1-guided contrast agents as tumor-detecting and imaging agents.
FN-EDB and TNC-C are upregulated in angiogenic blood vessels
during development and disease. To study the contribution of the an-
giogenesis-associated component to the homing of PL1, we next studied
the biodistribution of PL1-NWs in mice having a locally-induced an-
giogenic response. Ears of nude mice were intradermally injected with
an adenoviral vector driving the expression of VEGF-A164 (Fig. 4A).
Four days after the injection of the adenovirus when both FN-EDB and
TNC-C antigens were upregulated in angiogenic sites (Fig. S11), the
animals were injected with Texas Red/Evans Blue to visualize patent
blood vessels, followed by injection of PL1-NWs. In vivo multiphoton
analysis showed a> 3-fold increase in accumulation of PL1-NWs
Fig. 5. Analysis of distribution of PL1-functionalized and control AgNPs by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). (A) Schematic
illustration of the experimental procedure. Mice bearing orthotopic U87MG xenografts were injected i.v. with an equimolar mixture of targeted PL1-Ag109NPs and
control Ag107NPs. After 5 h circulation and perfusion, organs were snap-frozen and sectioned at 30 μm for LA-ICP-MS. GBM is apparent in the H&E stained
cryosections as an area of elevated cellular density. The region subjected to LA-ICP-MS analysis is outlined by a red box. (B–C) Distribution of control Ag107NPs
(upper panel) and targeted PL1-Ag109NPs (lower panel) in the tumor and surrounding brain parenchyma. The color scale corresponds to isotope counts per second;
the pixel size is 6.5×65 μm. Representative images of 3 independent experiments are shown. (D) Laser ablation line scans for Ag109/Ag107 profile using 40 μm spot
diameter. The ablation path is indicated by an arrow in H&E-stained glioma brain (left) and control (liver) tissue (right). The blue-dot graphs show the Ag109/
107 ratio on the laser ablation path across the tissue. (E) PL1-Ag109NP tissue distribution based on analysis of Ag109/107 ratios from line scans. PL1-AgNP
concentration in glioma is 2.6 to 30-fold higher than in the control tissues. Data are representative of 3 independent animals. P-value was determined by one-way
ANOVA Bonferroni's multiple comparisons test comparison with brain, lung and liver. Error bars: mean ± SD (n = 3 mice per group, each 5 data points per organ),
**p ˂ 0.01; ****p < 0.0001. Scale bars: 200 μm.
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(relative to nontargeted NWs) in the angiogenic vessels of adenovirus-
injected ear but not in the contralateral normal ear (Fig. 4). Background
labeling was seen in the blood vessels in the normal ear for both PL1
and control NWs (Fig. 4D–F, Fig. SM1-4). These results show that PL1
acts as an affinity ligand for angiogenic neovessels.
3.3. PL1-silver nanoparticles home to tumors
The structural and physicochemical properties of nanocarrier plat-
form can have a dramatic effect on biodistribution and targetability
with affinity ligands. To determine whether PL1 affinity targeting is
compatible with precision delivery of nanocarriers other than NWs, we
used silver nanoparticles (AgNP; Fig. S5)–a model nanoscale platform
Fig. 6. Antitumor activity of PL1-targeted nanoworms on U87MG and NCH421K glioma models and PL1-NW overlay assay on clinical glioblastomas. Mice bearing
subcutaneous U87MG and orthotopic NCH421K xenografts were i.v. injected with PBS, or different NWs formulations (D[KLAKLAK] 2-NWs, PL1-NWs or PL1-D
[KLAKLAK] 2-NWs; all at 5 mg iron/kg). The injections were performed every other day for a total of 10 injections (n = 8 mice/group). (A) Dynamics of tumor
volume in response to treatment with different NWs formulations. Statistical analyses were performed with two-way ANOVA Bonferroni's multiple comparisons test
and log-rank test (n = 8 mice/group), error bars: mean ± SEM; ns - P > 0.05; *** - p < 0.0001; (B) Kaplan-Meier survival analysis. Mice bearing intracranial
NCH421K tumors show statistically significant prolongation in survival when treated with PL1-D[KLAKLAK] 2-NWs compared to the control groups. (C) Frozen
sections of individual patient tumors were incubated with PL1-NWs or nontargeted NWs, immunostained, and examined by confocal microscopy. PL1-NWs show
binding to the tumor sections, and co-localize with EDB and TNC-C of all of the tested glioblastomas. Control non-targeted NWs exhibit no binding to the tumor
sections. Tissues were stained for FAM (anti-FITC, green), EDB (ScFv L19, red), TNC-C (ScFv G11, magenta) and nuclei (DAPI, blue). Scale bar: 100 μm for all panels.
(D) Colocalization analysis of PL1-NWs with EDB and TNC-C. Manders (M) correlation coefficient (0 - no colocalization; 1 - perfect colocalization) was calculated
using Fiji ImageJ Coloc 2 plugin. Error bars, mean ± SEM.
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that we have developed for biodistribution studies in vitro and in vivo.
AgNPs plasmonically enhance the emission from surface fluorophores
for ultrasensitive detection and can be isotopically barcoded for ultra-
sensitive detection by inductively-coupled plasma mass spectrometry
(ICP) [26].
To quantify in vivo biodistribution of systemic PL1-AgNPs in tumor-
bearing mice, we used ICP-MS to measure Ag. To overcome issues re-
lated to interanimal differences in dosing and physiological status of
tumors, we injected tumor-bearing mice with a cocktail of isotopically-
barcoded PL1-targeted and nontargeted AgNPs. Mice bearing ortho-
topic U87-MG GBM were i.v. injected with an equimolar mix of PL1-
Ag109NP and Ag107NP (Fig. 5). After 5 h circulation tissues were col-
lected and subjected to extract-based ICP-MS analysis and to line- and
rasterized laser ablation mapping of the isotopic content by ICP-MS
(LA-ICP-MS). ICP-MS analysis of tissue extracts demonstrated pre-
ferential tumor accumulation of PL1-Ag109NPs (~190 μg/kg of Ag109)
over control Ag107NPs (71 μg/kg of Ag107), and similar levels of the two
Ag isotopes in the control organs (Fig. S12). LA-ICP-MS mapping of
intratumoral heterogeneity of Ag109/Ag107 ratio showed heterogeneity,
with some areas showing a Ag109/Ag107 ratio of ~30 and above. Ana-
lysis of Ag109/Ag107 ratio with LA-ICP-MS showed that PL1 functiona-
lization increased AgNP homing to the GBMs on average ~2.7 fold
(Fig. 5B–E). The homing of the PL1-Ag109NPs was tumor-specific, as the
Ag109/Ag107 ratio in control organs was close to the input 1:1 ratio
(liver), or lower (in the lung and normal brain).
3.4. PL1-targeted proapoptotic nanoparticles have anti-GBM activity
To determine the effect of the PL1 functionalization on therapeutic
efficacy of anticancer nanoparticles, we used NWs coated with
D[KLAKLAK]2 peptide as a model nanodrug. Chimeric D[KLAKLAK]2
-PL1 was covalently linked to the NWs through a 5K-polyethylene
glycol (PEG) linker. In the first treatment study, we used s.c. U87MG
tumors that express abundant FN-EDB and TNC-C and display an an-
giogenic well-perfused vasculature [27]. We chose to use subcutaneous
model as it allowed us to monitor tumor size, rather than using survival,
as the endpoint. Mice bearing s.c. U87MG tumors were treated with
systemic injections every other day for 20 days. All mice from the PBS-
treated group reached 2 cm3 tumor volume allowed by animal ethics
committee within 37 days after tumor induction and were sacrificed
(Fig. 6A, Figs. S13–14). Tumor growth was significantly inhibited in the
PL1- D[KLAKLAK]2-NW-treated group (Fig. 6A), whereas only a slight
reduction in tumor growth was seen in animals treated with PL1-NWs,
or D[KLAKLAK]2-NWs.
Next, we evaluated the anti-GBM efficacy of PL1-D[KLAKLAK]2-NWs
in mice bearing human NCH421k orthotopic xenograft that displays a
combination of angiogenic and infiltrative features. The treatment was
initiated 3 days after tumor implantation. The median survival of
NCH421k mice treated with PL1-D[KLAKLAK]2-NWs was significantly
longer than of control mice treated with PBS, FAM-D[KLAKLAK]2-NWs,
or PL1-NWs (Fig. 6B). Moreover, one mouse in the NCH421k group that
received FAM-PL1- D[KLAKLAK]2-NWs survived 150 days without any
clinical signs, suggesting a cure. There were no overt systemic toxicities
as evidenced by stable body weight and normal histological appearance
of organs from the treated animals (Fig. S13). Staining of tumor sections
at the end of the treatment showed a significant decrease in the number
of tumor CD31-positive blood vessels in the FAM-PL1-D[KLAKLAK]2-
NW group compared with the control groups, whereas there was no
difference between the treatment groups in tumor Ki67-positive cells,
caspase-3-positive cells, CD11b, and CD68 macrophages or LYVE-1-
positive lymphatic vessels (Fig. S14).
Finally, we studied the binding of PL1-NWs to clinical GBM samples.
Cryosections of resected GBM were overlaid with FAM-PL1-NWs or
FAM-labeled control NWs, washed and subjected to confocal imaging.
PL1-NWs showed binding to all human GBM samples tested, with
binding primarily at perivascular structures as well as deep in the tumor
parenchyma (Fig. 6C–D). Overlaid PL1-NWs colocalized with tumor FN-
EDB and TNC-C that are highly overexpressed in clinical GBM samples
[28,29]. In contrast, control NWs showed only background fluores-
cence.
4. Discussion
Dual targeting with affinity ligands is a way of dealing with two
critical issues of affinity targeting, that the number of molecules of any
tumor-associated marker is limited and that there is considerable inter-
and intratumoral heterogeneity in the expression of such markers
[30,31]. Using two different tumor homing peptide modules in tandem
can improve biodistribution of payloads within malignant tissues, but
requires long, potentially immunogenic peptides [32]. Here we describe
identification and preclinical development of a bispecific short peptide
that contains overlapping binding sites for two clinically relevant ECM
proteins, FN-EBD and TNC-C. Targeting with PL1 peptide increases
homing of model nanoparticles in the FN-EDB and TNC-C positive areas
in tumors and in angiogenic sites induced by overexpression of VEGF1 –
a known inducer of FN-EDB expression [33,34]. In tumor tissue, FN-
EDB and TNC-C have non-overlapping expression domains and tar-
geting both receptors increases the likelyhood of PL1-receptor inter-
action and enthalpic gain for target-selective NP adsorption [35].
Systemically given PL1-functionalized nanoparticles home to tu-
mors through participation of both receptor proteins. That this is the
case, is evidenced by the fact that in vivo blockade of either receptor by
a neutralizing antibody substantially decreases in FAM-PL1-NW accu-
mulation in terms of both fluorescence intensity and area positive for
the presence of the nanoparticles. Thus, dual targeting does increase the
efficacy of the tumor targeting.
Low quantity and poor availability of receptors for affinity targeting
have been recognized as major bottlenecks in the development of pre-
cision drugs. Tumor-associated ECM is higher capacity target for affi-
nity delivery than membrane-bound receptors. For example, average
molar representation of TNC subunits in tumor proteome is more than 2
orders of magnitude higher than the threshold level of HER2 considered
positive and suitable for Herceptin-based therapies [36,37] ECM-tar-
geted affinity therapeutics are not subject to lysosomal drug seques-
tration and inactivation upon endocytosis and act across tumor-resident
cell populations including cells unaffected by therapeutic strategies
aimed at the bulk of the tumor cells such as tumor stem cells, tumor
fibroblasts (CAFs) and macrophages (TAMs) [38].
FN-EBD and TNC are abundant components of the tumor ECM and
predictive of adverse outcome. Over the years, several monospecific
targeting ligands have been developed for both FN-EDB [such as FN-
EDB-ScFV L19 [39]] and TNC [e.g. TNC-C-ScFV G11 [14], TNC aptamer
[40], and TNC-binding FHK peptide [41]]. Importantly, ECM-binding
affinity ligands are compatible with targeting of intracellularly acting
anticancer drugs: for example, ECM-binding antibody drug conjugates
are able to efficiently release their drug payloads in the extracellular
environment to exert a potent therapeutic activity [20,38]. We ob-
served that treatment with systemic PL1- D[KLAKLAK]2-NWs sig-
nificantly reduced tumor volume and increased the lifespan of tumor
mice. To exert its apoptotic activity D[KLAKLAK]2 peptide must be
primarily taken up in the cells and translocate to the mitochondria
[42,43]. D[KLAKLAK]2, which is an amphiphilic peptide, is known to
act as an internalizing agent, and D[KLAKLAK]2-NPs have been reported
to be internalized into cells after having been brought to tumor tissue
by a non-internalizing peptide [42]. Likewise, PL1- D[KLAKLAK]2-NWs
introduced into tumor microenvironment are likely taken up in the cells
in D[KLAKLAK]2-dependent manner. Short peptidic ligands tend to
binds to conserved functionally important binding pockets on target
molecules [5]. Both FN-EDB and TNC-C are involved in regulating en-
dothelial cell behavior and plasticity during tumor angiogenesis. Our
ongoing studies will elucidate PL1 binding site(s) on FN-EDB and TNC-
C and establish whether engagement of PL1 peptide with its targets
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alone may have an effect on tumor growth.
We used AgNPs to validate PL1 as a systemic, tumor-selective affi-
nity ligand for nanoscale payloads because these NPs offer significant
advantages regarding detection in tissues; they can be isotopically
barcoded for ultrasensitive internally controlled detection and spatial
mapping using LA-ICP-MS [44]. Tumor accumulation of PL1, and PL1-
NPs in particular, may be limited by the accessibility of extravascular
TNC-C and FN-EDB for blood-borne probes, which is likely to require
leaky tumor blood vessels. Co-administration with tumor penetrating
iRGD peptide has been shown to robustly increase the access of blood-
borne probes for tumor HER2 (~6 fold) and αvβ3 integrin (~4 fold)
[21]. It will be of great interest to explore if co-administered iRGD is
also able to boost tumor accumulation of PL1-targeted payloads. An-
other aspect that must be systematically addressed is the selection of
the type of drug and carrier best suited for PL1 targeting. Further stu-
dies are required to determine the effect of PL1 conjugation on the
efficacy and toxicity profiles of conventional chemotherapeutics de-
signed to be released in the extracellular space (e.g. through proteolytic
cleavage or by reduction of disulfide bonds) [45,46] and on extra-
cellularly-acting cytokines such as IL-2 and TNF-α [47,48]. Finally, the
expression of both of the ECM targets of PL1 correlates with the cancer
prognosis and therapeutic response profiles, suggesting that PL1 guided
molecular imaging probes may have diagnostic and prognostic appli-
cations.
In summary, bispecific PL1 peptide allows specific targeting of solid
tumors positive for expression of FN-EDB and/or TNC-C. As FN-EDB
domain is fully and TNC-C domain is 96% conserved between mice and
humans, it is possible to envision clinical development for PL1-based
approaches for precision cancer drug delivery and application of PL1-
guided imaging agents as companion diagnostics to stratify patients for
therapeutic targeting FN-EDB and TNC-C-positive tumors and to
monitor the efficacy of anticancer interventions.
Significance
Simultaneous affinity targeting of two or more markers in the tumor
microenvironment may overcome the spatiotemporal heterogeneity in
expression of target molecules and alleviate issues related to the limited
number of available receptors for targeting ligands. We describe de-
velopment of a simple 12 amino acid homing peptide for dual targeting
of fibronectin and tenascin isoforms in the tumor extracellular matrix
(ECM). FN-EDB and TNC-C domains targeted by the peptide are fully
conserved between mouse and human and are already developed as
targets of monospecific single chain antibodies. Features of PL1 peptide
– dual targeting of abundant tumor-associated ECM components, spe-
cificity in binding to clinically relevant targets, small size, and human
reactivity – warrant follow-up preclinical and clinical development.
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